02 Jul 2014, BioSpectrum Bureau , BioSpectrum
Singapore: US based contract research firm, AMRI, with operations in Asia, has acquired Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners and a contract manufacturer of highly complex injectable drug products, in $110 million deal.
Altaris Capital Partners is a US based investment firm focused exclusively on healthcare industry.
The transaction is consistent with AMRI's strategy to be the preeminent supplier of custom and complex drug product development and manufacturing services to the pharmaceutical industry.
OsoBio has its strength in large-scale commercial production and is expected to complement AMRI's early stage drug product manufacturing capabilities.
AMRI informed that the company financed the transaction with cash on hand and anticipates full year run-rate synergies of approximately $3.0 million of EBITDA within 12 months of closing.